← Back to Screener
Kura Oncology, Inc. (KURA)
Price$9.78
Favorite Metrics
Price vs S&P 500 (26W)-10.47%
Price vs S&P 500 (4W)7.70%
Market Capitalization$863.87M
All Metrics
P/CF (Annual)5.80x
Book Value / Share (Quarterly)$1.98
P/TBV (Annual)1.69x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-0.80
Price vs S&P 500 (YTD)-10.97%
Net Profit Margin (TTM)-412.95%
EPS (TTM)$-3.18
10-Day Avg Trading Volume1.30M
EPS Excl Extra (TTM)$-3.18
EPS (Annual)$-3.18
ROI (Annual)-151.58%
Gross Margin (Annual)99.92%
Cash / Share (Quarterly)$7.59
Revenue Growth QoQ (YoY)-67.83%
ROA (Last FY)-37.74%
EBITD / Share (TTM)$-3.45
ROE (5Y Avg)-59.72%
Operating Margin (TTM)-449.94%
Cash Flow / Share (Annual)$-0.80
P/B Ratio4.96x
P/B Ratio (Quarterly)5.19x
Net Income / Employee (Annual)$-1
EV / Revenue (TTM)10.74x
Net Interest Coverage (TTM)-252.07x
ROA (TTM)-39.61%
EPS Incl Extra (Annual)$-3.18
Current Ratio (Annual)6.06x
Quick Ratio (Quarterly)5.78x
3-Month Avg Trading Volume1.54M
52-Week Price Return68.35%
EV / Free Cash Flow (Annual)5.19x
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$5.79
P/S Ratio (Annual)12.80x
Asset Turnover (Annual)0.09x
52-Week High$12.49
EPS Excl Extra (Annual)$-3.18
CapEx CAGR (5Y)25.06%
Tangible BV CAGR (5Y)39.39%
26-Week Price Return-1.73%
Quick Ratio (Annual)5.78x
13-Week Price Return3.42%
Total Debt / Equity (Annual)0.06x
Current Ratio (Quarterly)6.06x
Enterprise Value$724.477
Asset Turnover (TTM)0.10x
Book Value / Share Growth (5Y)-26.48%
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-412.51%
Cash / Share (Annual)$7.59
3-Month Return Std Dev50.05%
Net Income / Employee (TTM)$-1
ROE (Last FY)-160.03%
Net Interest Coverage (Annual)-122.19x
EPS Basic Excl Extra (Annual)$-3.18
EV / Free Cash Flow (TTM)8.35x
Total Debt / Equity (Quarterly)0.06x
EPS Incl Extra (TTM)$-3.18
ROI (TTM)-99.07%
P/S Ratio (TTM)12.80x
Revenue / Share (Annual)$0.77
Tangible BV / Share (Annual)$6.15
Price vs S&P 500 (52W)33.25%
Year-to-Date Return-6.83%
5-Day Price Return11.01%
EPS Normalized (Annual)$-3.18
ROA (5Y Avg)-29.77%
Net Profit Margin (Annual)-412.95%
Month-to-Date Return19.07%
Cash Flow / Share (TTM)$-2.01
EBITD / Share (Annual)$-3.45
Operating Margin (Annual)-449.94%
LT Debt / Equity (Annual)0.06x
P/CF (TTM)8.88x
ROI (5Y Avg)-57.52%
LT Debt / Equity (Quarterly)0.06x
EPS Basic Excl Extra (TTM)$-3.18
P/TBV (Quarterly)1.65x
P/B Ratio (Annual)5.19x
Pretax Margin (TTM)-412.51%
Book Value / Share (Annual)$1.98
Price vs S&P 500 (13W)0.55%
Beta0.38x
P/FCF (Annual)6.45x
Revenue / Share (TTM)$0.77
ROE (TTM)-102.59%
52-Week Low$5.45
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.14
4.14
4.14
4.14
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
KURAKura Oncology, Inc. | 12.80x | — | — | — | $9.78 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Kura Oncology is a clinical-stage biopharmaceutical company focused on developing precision oncology therapies. Its pipeline comprises small molecule drug candidates designed to target specific cancer signaling pathways.